After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...

+ Major support for Amanpour and Company is provided by Jim Attwood and Leslie Williams, Candace King Weir, the Sylvia A. and Simon B. Poyta Programming Endowment to Fight Antisemitism, the Leila ...

Vanessa Leroy / Bloomberg via Getty Images Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.

(Reuters) - Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up 34% in ...

Biogen offers $7.22 per share to acquire Sage Therapeutics. Goldman Sachs projects Zurzuvae could reach $700 million in global sales by 2034. Get Pro-Level Earnings Insights Before the Market ...

The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the ...

After a 2024 marred by a series of trial failures, Sage Therapeutics Inc. has received an acquisition offer from longtime partner Biogen Inc. on the eve of the biggest biotech event of the year.

Across the recent three months, 18 analysts have shared their insights on Biogen BIIB, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates their ...

Biogen has offered to purchase Sage’s outstanding shares for $7.22 each, according to a securities filing from Friday. The proposal values Sage at around $442 million. A yearslong partner of ...